reconstituting aod9604 2mg AOD9604 2mg

Dual mechanism addresses both insulin and glucagon pathways

Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight

This rigorous methodology minimizes bias and allows for accurate attribution of adverse effects to the intervention rather than background health conditions or placebo effects

These injections are unapproved compounded products that have not been reviewed by the FDA for safety, effectiveness, or quality

The compound has served as a biochemical tool to probe how NNMT activity intersects with insulin signaling and glucose utilization pathways in research settings

After the initial six weeks, the injections can be tapered down to being given less frequently, often once every one to two months